News

Venus Remedies announced that the 37th Annual General Meeting(AGM) of the company will be held on 20 August 2026.

Venus Remedies announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Venus Remedies rose 126.19% to Rs 47.50 crore in the quarter ended March 2026 as against Rs 21.00 crore during the previous quarter ended March 2025. Sales rose 33.05% to Rs 259.40 crore in the quarter ended March 2026 as against Rs 194.97 crore during the previous quarter ended March 2025.For the full year,net profit rose 126.81% to Rs 102.79 crore in the year ended March 2026 as against Rs 45.32 crore during the previous year ended March 2025. Sales rose 17.88% to Rs 769.60 crore in the year ended March 2026 as against Rs 652.89 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.40194.97 33 769.60652.89 18 OPM %24.4514.87 -19.1410.50 - PBDT68.3635.75 91 159.8284.42 89 PBT61.6131.04 98 134.1661.91 117 NP47.5021.00 126 102.7945.32 127 Powered by Capital Market - Live News

Net profit of Venus Remedies rose 193.78% to Rs 43.45 crore in the quarter ended March 2026 as against Rs 14.79 crore during the previous quarter ended March 2025. Sales rose 31.65% to Rs 259.01 crore in the quarter ended March 2026 as against Rs 196.74 crore during the previous quarter ended March 2025.For the full year,net profit rose 88.98% to Rs 99.31 crore in the year ended March 2026 as against Rs 52.55 crore during the previous year ended March 2025. Sales rose 19.28% to Rs 768.73 crore in the year ended March 2026 as against Rs 644.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.01196.74 32 768.73644.47 19 OPM %22.9512.83 -18.7211.64 - PBDT64.0829.33 118 155.3790.77 71 PBT57.5724.84 132 130.6869.15 89 NP43.4514.79 194 99.3152.55 89 Powered by Capital Market - Live News

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company`s move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets. Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.